Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Promising targets beyond FLT3 in AML: IDH1/2 & menin

Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, comments on promising agents targeting IDH1/2, including ivosidenib, enasidenib, and olutasidenib, and agents targeting menin, including ziftomenib and revumenib, for patients with acute myeloid leukemia (AML). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Abbvie, Astellas, BerGenBio, Daiichi Sankyo, Genentech, Immunogen–advisory board
Abbvie, Astellas, Daiichi Sankyo, Foghorn–consulting
Abbvie, Astellas, Daiichi Sankyo, FujiFilm, Syndax–research funding (to institution)